Author

Jessie M. Barra

University of Florida HealthORCID 0000-0002-6456-9293Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioengineering· 3 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cell-cell communication· 1

Frequent Co-Authors

Holger A. RussiD· 5 shared Andrew M. LaddiD· 3 shared Edward A. PhelpsiD· 2 shared Matthew E. BrowniD· 2 shared Todd M. BruskoiD· 2 shared Aaron W. MichelsiD· 1 shared Adrienne E. WideneriD· 1 shared Alexandra E. CuaycaliD· 1 shared

Activity by Year

2024-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersBioengineering

Holger A. RussORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Beta cell reactivity defines disease-relevant pancreatic CD8 T cells in type 1 diabetes

Amanda M. Anderson, Laurie G. Landry, Jessie M. Barra, Kristen L. Wells, Ali H. Shilleh, Roberto Castro-Gutiérrez, Andrew M. Ladd, Megan DeNicola, Jenny Aurielle B. Babon, Roberto Mallone, Sally C. Kent, Aaron W. Michels, Holger A. Russ, Maki Nakayama

This study identifies beta cell reactivity as a key feature distinguishing T1D-associated CD8 T cells from other pancreatic T cells.

bioRxiv · Jun 10, 2026 · PreprintImmunology

Anti-CD3 microporous annealed particle hydrogel protects stem cell derived beta cells from autoreactive T cells

Adrienne E. Widener, Cameron T. Manson, Jessie M. Barra, Christopher P. Spencer, Amanda D Grodman, Andrew M. Ladd, Holger A. Russ, Edward A. Phelps

This study develops a CD3-functionalized hydrogel to protect stem cell-derived beta cells from immune rejection in diabetes therapy.

bioRxiv · Nov 11, 2025 · PreprintBioengineering

Human Stem Cell-Derived β-cells Expressing An Optimized CD155 Reduce Cytotoxic Immune Cell Function for Application in Type 1 Diabetes

Matthew E. Brown, Jessie M. Barra, Mariana Pina, James Proia, Todd M. Brusko, Holger A. Russ

This study shows that human stem cell-derived β-cells expressing a high-affinity CD155 variant reduce immune cell cytotoxicity, improving their potential for type 1 diabetes therapy.

Science Advances · Nov 7, 2025Peer-reviewedImmunology

Inhibition of cell-mediated immunity in type 1 diabetes by beta cell-targeted PD-1 agonists in pancreas tissue slices

Matthew W. Becker, Matthew E. Brown, Katherine Wiseman, Ana Laura Chiodetti, Mollie K. Huber, Alexandra E. Cuaycal, Pumin Sintara, Sandra Mara Ferreira, Dylan Smurlick, Jessie M. Barra, Andrew M. Ladd, Denise Minerva Drotar, Mark A. Atkinson, Peter Weber, Hussein Al‐Mossawi, , Edward A. Phelps

This study shows that ImmTAAI, a beta cell-targeted PD-1 agonist, inhibits T cell activity in human type 1 diabetes by increasing T cell motility and reducing cytokine secretion.

bioRxiv · Oct 21, 2025 · PreprintBioengineering

Peptide Coated Polycaprolactone-Benzalkonium Chloride Nanocapsules for Targeted Drug Delivery to the Pancreatic β-Cell

Jillian Collins, Jessie M. Barra, Keifer Holcomb, Andres Ocampo, Ashton Fremin, Austin Kratz, Jubril Olayinka Akolade, Julianna K. Hays, Ali Shilleh, Amit Sela, David J. Hodson, Johannes Broichhagen, Holger A. Russ, Nikki L. Farnsworth

This paper develops peptide-coated nanocapsules for targeted drug delivery to pancreatic β-cells, showing effective in vitro and in vivo targeting and cargo delivery.

ACS Applied Bio Materials · Sep 24, 2024Peer-reviewedBioengineering